Please login to the form below
CHMP 2019
This page shows the latest CHMP 2019 news and features for those working in and with pharma, biotech and healthcare.
CHMP backs Lynparza in breast cancer, Dupixent in asthma
PARP inhibitor Lynparza (olaparib) – already making big headway in ovarian cancer – was given a positive opinion by the CHMP for BRCA-mutated, HER2-negative breast cancer, around a year after the ... Two rare diseases are on track to get their new
Latest news
-
Shire’s angioedema drug Takhzyro recommended in Europe
The European Medicines Agency's CHMP committee has recommended Shire’s Takhzyro (lanadelumab), a new rare disease treatment which has blockbuster potential. ... Lanadelumab had been granted accelerated assessment by the EMA, which cut the evaluation
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Health Unlimited
Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
